Ameliorating antipsychotic-induced weight gain by betahistine: Mechanisms and clinical implications

Kane, 2010, Past and present progress in the pharmacologic treatment of schizophrenia, J. Clin. Psychiatry, 71, 1115, 10.4088/JCP.10r06264yel Krill, 2014, Metabolic consequences of second-generation antipsychotics in youth: appropriate monitoring and clinical management, Adolesc. Health Med. Ther., 5, 171 Lambert, 2011, Managing the metabolic adverse effects of antipsychotic drugs in patients with psychosis, Aust. Prescr., 34, 97, 10.18773/austprescr.2011.057 Meltzer, 2013, Update on typical and atypical antipsychotic drugs, Annu. Rev. Med., 64, 393, 10.1146/annurev-med-050911-161504 Cuerda, 2014, The effects of second-generation antipsychotics on food intake: resting energy expenditure and physical activity, Eur. J. Clin. Nutr., 68, 146, 10.1038/ejcn.2013.253 Deng, 2013, Effects of antipsychotic medications on appetite weight, and insulin resistance, Endocrinol. Metab. Clin. North Am., 42, 545, 10.1016/j.ecl.2013.05.006 Milano, 2013, Antipsychotic drugs opposite to metabolic risk: neurotransmitters: neurohormonal and pharmacogenetic mechanisms underlying with weight gain and metabolic syndrome, Open Neurol. J., 7, 23, 10.2174/1874205X01307010023 Correll, 2011, Antipsychotic drugs and obesity, Trends Mol. Med., 17, 97, 10.1016/j.molmed.2010.10.010 Osuntokun, 2011, Metabolic parameters in patients treated with olanzapine or other atypical antipsychotics, J. Psychopharmacol. (Oxf.), 25, 630, 10.1177/0269881110368872 Warikoo, 2014, Adherence and continuation of treatment with first- and second-generation antipsychotics in schizophrenia, Indian J. Psychol. Med., 36, 33, 10.4103/0253-7176.127244 Harris, 2013, Schizophrenia: metabolic aspects of aetiology: diagnosis and future treatment strategies, Psychoneuroendocrinology, 38, 752, 10.1016/j.psyneuen.2012.09.009 Deng, 2010, The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain, Prog. Neuropsychopharmacol. Biol. Psychiatry., 34, 1, 10.1016/j.pnpbp.2009.11.009 He, 2013, The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain, CNS Drugs, 27, 423, 10.1007/s40263-013-0062-1 Kroeze, 2003, H1-Histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs, Neuropsychopharmacology, 28, 519, 10.1038/sj.npp.1300027 Attux, 2011, The effectiveness of a non-pharmacological intervention for weight gain management in severe mental disorders: results from a national multicentric study, Rev. Bras. Psiquiatr., 33, 117, 10.1590/S1516-44462011000200005 G. Faulkner, T.A. Cohn, Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications.[erratum appears in Can J Psychiatry. 2006 Aug; 51 (9): 620]. Canadian Journal of Psychiatry − Revue Canadienne de Psychiatrie 51 (2006) 502-511. Fiedorowicz, 2012, Systematic review and meta-analysis of pharmacological interventions for weight gain from antipsychotics and mood stabilizers, Curr. Psychiatry Rev., 8, 25, 10.2174/157340012798994867 Baptista, 2008, Pharmacological management of atypical antipsychotic-induced weight gain, CNS Drugs, 22, 477, 10.2165/00023210-200822060-00003 Maayan, 2010, Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis, Neuropsychopharmacology, 35, 1520, 10.1038/npp.2010.21 Jarskog, 2013, Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder, Am. J. Psychiatry, 170, 1032, 10.1176/appi.ajp.2013.12010127 Morrison, 2002, Metformin for weight loss in pediatric patients taking psychotropic drugs, Am. J. Psychiatry, 159, 655, 10.1176/appi.ajp.159.4.655 Shin, 2009, Metformin for weight control in pediatric patients on atypical antipsychotic medication, J. Child Adolesc. Psychopharmacol., 19, 275, 10.1089/cap.2008.094 Weaver, 2010, Use of metformin to control clozapine-associated weight gain in an adolescent with schizoaffective disorder, J. Child Adolesc. Psychopharmacol., 20, 153, 10.1089/cap.2010.2022 Hu, 2014, Metformin and berberine prevent olanzapine-induced weight gain in rats, PLoS One, 9, e93310, 10.1371/journal.pone.0093310 Baptista, 2009, Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind placebo-controlled, 12-week trial, Pharmacopsychiatry, 42, 14, 10.1055/s-0028-1085438 Ehret, 2010, The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis, J. Clin. Psychiatry, 71, 1286, 10.4088/JCP.09m05274yel Biedermann, 2014, Sibutramine in the treatment of antipsychotic-induced weight gain: a pilot study in patients with schizophrenia, Int. Clin. Psychopharmacol., 29, 181, 10.1097/YIC.0000000000000022 Das, 2012, Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments, Ann. Clin. Psychiatry, 24, 225 Domecq, 2015, Clinical review: drugs commonly associated with weight change: a systematic review and meta-analysis, J. Clin. Endocrinol. Metab., 100, 363, 10.1210/jc.2014-3421 Generali, 2014, Topiramate: antipsychotic-induced weight gain, Hosp. Pharm., 49, 345, 10.1310/hpj4904-345 Ghanizadeh, 2013, The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: a randomized double-blind, placebo-controlled clinical trial, Schizophr. Res., 147, 110, 10.1016/j.schres.2013.03.021 Mizuno, 2014, Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis, Schizophr. Bull., 10.1093/schbul/sbu030 Provensi, 2015, The histaminergic system as a target for the prevention of obesity and metabolic syndrome, Neuropharmacology, 1 Haas, 2008, Histamine in the nervous system, Physiol. Rev., 88, 1183, 10.1152/physrev.00043.2007 Masaki, 2010, Neuronal histamine and its receptors: implication of the pharmacological treatment of obesity, Curr. Med. Chem., 17, 4587, 10.2174/092986710794182944 Jorgensen, 2006, Increased susceptibility to diet-induced obesity in histamine-deficient mice, Neuroendocrinology, 83, 289, 10.1159/000095339 Brown, 2001, The physiology of brain histamine, Prog. Neurobiol., 63, 637, 10.1016/S0301-0082(00)00039-3 Masaki, 2006, The hypothalamic H1 receptor: a novel therapeutic target for disrupting diurnal feeding rhythm and obesity, Trends Pharmacol. Sci., 27, 279, 10.1016/j.tips.2006.03.008 Lintunen, 1998, Postnatal expression of H1-receptor mRNA in the rat brain: correlation to L-histidine decarboxylase expression and local upregulation in limbic seizures, Eur. J. Neurosci., 10, 2287, 10.1046/j.1460-9568.1998.00240.x Arrang, 1983, Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor, Nature, 302, 832, 10.1038/302832a0 Strakhova, 2009, Localization of histamine H4 receptors in the central nervous system of human and rat, Brain Res., 1250, 41, 10.1016/j.brainres.2008.11.018 Passani, 2011, The histamine H3 receptor and eating behavior, J. Pharmacol. Exp. Ther., 336, 24, 10.1124/jpet.110.171306 Park, 1999, Increased binding at 5-HT1A 5-HT1B, and 5-HT2A receptors and 5-HT transporters in diet-induced obese rats, Brain Res., 847, 90, 10.1016/S0006-8993(99)02055-7 Sethi, 2012, Loss of histaminergic modulation of thermoregulation and energy homeostasis in obese mice, Neuroscience, 217, 84, 10.1016/j.neuroscience.2012.04.068 Clineschmidt, 1973, Histamine: intraventricular injection suppresses ingestive behavior of the cat, Arch. Int. Pharmacodyn. Ther., 206, 288 Itowi, 1988, Changes in the feeding behavior of rats elicited by histamine infusion, Physiol. Behav., 44, 221, 10.1016/0031-9384(88)90142-4 Lecklin, 1998, Effects of intracerebroventricularly infused histamine and selective H1: H2 and H3 agonists on food and water intake and urine flow in Wistar rats, Brain Res., 793, 279, 10.1016/S0006-8993(98)00186-3 Fulop, 2003, Hyperleptinemia visceral adiposity, and decreased glucose tolerance in mice with a targeted disruption of the histidine decarboxylase gene, Endocrinology, 144, 4306, 10.1210/en.2003-0222 Wang, 2010, Histamine regulation in glucose and lipid metabolism via histamine receptors: model for nonalcoholic steatohepatitis in mice, Am. J. Pathol., 177, 713, 10.2353/ajpath.2010.091198 Davoodi, 2008, Comparative effects of olanzapine and ziprasidone on hypophagia induced by enhanced histamine neurotransmission in the rat, Behav. Pharmacol., 19, 121, 10.1097/FBP.0b013e3282f62c66 Masaki, 2004, Involvement of hypothalamic histamine H1 Receptor in the regulation of feeding rhythm and obesity, Diabetes, 53, 2250, 10.2337/diabetes.53.9.2250 Poole, 2008, Histamine depolarizes neurons in the dorsal vagal complex, Neurosci. Lett., 432, 19, 10.1016/j.neulet.2007.11.055 Tecott, 1995, Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors, Nature, 374, 542, 10.1038/374542a0 Masaki, 2001, Targeted disruption of histamine H1-receptor attenuates regulatory effects of leptin on feeding adiposity, and UCP family in mice, Diabetes, 50, 385, 10.2337/diabetes.50.2.385 Umehara, 2010, Innervation of histamine neurons in the caudal part of the arcuate nucleus of hypothalamus and their activation in response to food deprivation under scheduled feeding, Methods Find. Exp. Clin. Pharmacol., 32, 733, 10.1358/mf.2010.32.10.1545781 He, 2014, Hypothalamic histamine H1 receptor-AMPK signaling time-dependently mediates olanzapine-induced hyperphagia and weight gain in female rats, Psychoneuroendocrinology, 42, 153, 10.1016/j.psyneuen.2014.01.018 Coccurello, 2010, Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design, Pharmacol. Ther., 127, 210, 10.1016/j.pharmthera.2010.04.008 Correll, 2008, Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients, Int. Rev. Psychiatry, 20, 195, 10.1080/09540260801889179 Matsui-Sakata, 2005, Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus, Drug Metab. Pharmacokinet., 20, 368, 10.2133/dmpk.20.368 Panariello, 2011, Weight gain, schizophrenia and antipsychotics: new findings from animal model and pharmacogenomic studies, Schizophr. Res. Treat., 2011, 459284 Stahl, 2009, Which comes first: atypical antipsychotic treatment or cardiometabolic risk, Acta Psychiatr. Scand., 119, 171, 10.1111/j.1600-0447.2008.01334.x Han, 2008, Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression, Psychoneuroendocrinology, 33, 569, 10.1016/j.psyneuen.2008.01.018 Kim, 2007, Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase, Proc. Natl. Acad. Sci. U.S.A., 104, 3456, 10.1073/pnas.0611417104 Lian, 2014, Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic: nPY and AMPK pathways, Psychoneuroendocrinology, 48, 77, 10.1016/j.psyneuen.2014.06.010 Lian, 2014, Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment, PLoS One, 9, e104160, 10.1371/journal.pone.0104160 Vehof, 2011, Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication, Psychopharmacology (Berl.), 216, 257, 10.1007/s00213-011-2211-x WysokinskiI, 2014, Mechanisms of increased appetite and weight gain induced by psychotropic medications, J. Adv. Clin. Pharmacol., 1, 12, 10.14205/2312-3710.2014.01.01.3 Erhart, 1998, Novel antipsychotics and new onset diabetes, Biol. Psychiatry, 44, 778, 10.1016/S0006-3223(98)00100-0 Wirshing, 1999, Novel antipsychotics: comparison of weight gain liabilities, J. Clin. Psychiatry, 60, 358, 10.4088/JCP.v60n0602 Chervinsky, 1994, Once daily loratadine versus astemizole once daily, Ann. Allergy, 73, 109 Saleh, 1979, Ingestive behavior and composition of weight change during cyproheptadine administration, Int. J. Obes., 3, 213 Sant'Anna, 2014, Use of cyproheptadine in young children with feeding difficulties and poor growth in a pediatric feeding program, J. Pediatr. Gastroenterol. Nutr., 59, 674, 10.1097/MPG.0000000000000467 Silverstone, 1975, The effect of cyproheptadine on hunger: calorie intake and body weight in man, Psychopharmacologia, 40, 335, 10.1007/BF00421472 Jassim, 2012, Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat, Psychopharmacology (Berl.), 219, 783, 10.1007/s00213-011-2397-y Liu, 2015, Betahistine co-treatment ameliorates dyslipidemia induced by chronic olanzapine treatment in rats through modulation of hepatic AMPKalpha-SREBP-1 and PPARalpha-dependent pathways, Pharmacol. Res., 100, 36, 10.1016/j.phrs.2015.07.023 Lundius, 2010, Histamine influences body temperature by acting at H1 and H3 receptors on distinct populations of preoptic neurons, J. Neurosci., 30, 4369, 10.1523/JNEUROSCI.0378-10.2010 Teff, 2011, Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism, Physiol. Behav., 104, 590, 10.1016/j.physbeh.2011.05.033 Panula, 2013, The histaminergic network in the brain: basic organization and role in disease, Nat. Rev. Neurosci., 14, 4724, 10.1038/nrn3526 Pillot, 2002, A detailed mapping of the histamine H3 receptor and its gene transcripts in rat brain, Neuroscience, 114, 173, 10.1016/S0306-4522(02)00135-5 Takahashi, 2002, Targeted disruption of H3 receptors results in changes in brain histamine tone leading to an obese phenotype, J. Clin. Invest., 110, 1791, 10.1172/JCI15784 Threlfell, 2004, Histamine H3 receptors inhibit serotonin release in substantia nigra pars reticulata, J. Neurosci., 24, 8704, 10.1523/JNEUROSCI.2690-04.2004 E. SchlickerI. Marr. The moderate affinity of clozapine at H<sub>3</sub> receptors is not shared by its two major metabolites and by structurally related and unrelated atypical neuroleptics. Naunyn Schmiedebergs Arch Pharmacol, 353 (1996) 290-294. Vohora, 2012, Histamine H3 receptor antagonists/inverse agonists on cognitive and motor processes: relevance to Alzheimer's disease ADHD, schizophrenia, and drug abuse, Front. Syst. Neurosci., 6, 72, 10.3389/fnsys.2012.00072 Gomez-Ramirez, 2002, Presynaptic H3 autoreceptors modulate histamine synthesis through cAMP pathway, Mol. Pharmacol., 61, 239, 10.1124/mol.61.1.239 Chiba, 2009, Acute central administration of immepip a histamine H3 receptor agonist, suppresses hypothalamic histamine release and elicits feeding behavior in rats, Brain Res. Bull., 79, 37, 10.1016/j.brainresbull.2008.12.012 Murotani, 2011, Possible involvement of serotonin 5-HT2 receptor in the regulation of feeding behavior through the histaminergic system, Neuropharmacology, 61, 228, 10.1016/j.neuropharm.2011.04.003 Kohno, 2011, AMP-activated protein kinase activates neuropeptide Y neurons in the hypothalamic arcuate nucleus to increase food intake in rats, Neurosci. Lett., 499, 194, 10.1016/j.neulet.2011.05.060 Minokoshi, 2004, AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus, Nature, 428, 569, 10.1038/nature02440 Martin, 2006, Diet-induced obesity alters AMP kinase activity in hypothalamus and skeletal muscle, J. Biol. Chem., 281, 18933, 10.1074/jbc.M512831200 Kahn, 2005, AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism, Cell Metab., 1, 15, 10.1016/j.cmet.2004.12.003 Kola, 2008, Role of AMP-activated protein kinase in the control of appetite, J. Neuroendocrinol., 20, 942, 10.1111/j.1365-2826.2008.01745.x Lage, 2008, AMPK: a metabolic gauge regulating whole-body energy homeostasis, Trends Mol. Med., 14, 539, 10.1016/j.molmed.2008.09.007 Ramírez, 2013, Hypothalamic ceramide levels regulated by CPT1C mediate the orexigenic effect of ghrelin, Diabetes, 62, 2329, 10.2337/db12-1451 Ronnett, 2009, AMPK in the brain: its roles in energy balance and neuroprotection, J. Neurochem., 109, 17, 10.1111/j.1471-4159.2009.05916.x Kang, 2012, Desipramine inhibits histamine H1 receptor-induced Ca2+ signaling in rat hypothalamic cells, PLoS One, 7, e36185, 10.1371/journal.pone.0036185 Sejima, 2011, A role for hypothalamic AMP-activated protein kinase in the mediation of hyperphagia and weight gain induced by chronic treatment with olanzapine in female rats, Cell. Mol. Neurobiol., 31, 985, 10.1007/s10571-011-9663-8 Skrede, 2014, Olanzapine depot formulation in rat: A step forward in modelling antipsychotic-induced metabolic adverse effects, Int. J. Neuropsychopharmacol., 17, 91, 10.1017/S1461145713000862 Fernø, 2011, Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation, PLoS One, 6, e20571, 10.1371/journal.pone.0020571 Martins, 2010, Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance, Diabetes, 59, 2418, 10.2337/db10-0449 Ak, 2013, The investigation of leptin and hypothalamic neuropeptides role in first attack psychotic male patients: olanzapine monotherapy, Psychoneuroendocrinology, 38, 341, 10.1016/j.psyneuen.2012.06.012 Joly-Amado, 2014, The hypothalamic arcuate nucleus and the control of peripheral substrates, Best Pract. Res. Clin. Endocrinol. Metab., 28, 725, 10.1016/j.beem.2014.03.003 Sobrino Crespo, 2014, Peptides and food intake, Front. Endocrinol., 5, 58, 10.3389/fendo.2014.00058 Zhang, 2014, Hypothalamus-adipose tissue crosstalk: Neuropeptide y and the regulation of energy metabolism, Nutr. Metab. (Lond.), 11, 10.1186/1743-7075-11-27 Bradley, 2005, Neuropeptides, including neuropeptide Y and melanocortins: mediate lipolysis in murine adipocytes, Obes. Res., 13, 653, 10.1038/oby.2005.73 Brothers, 2010, Therapeutic potential of neuropeptide Y (NPY) receptor ligands, EMBO Mol. Med., 2, 429, 10.1002/emmm.201000100 Larhammar, 1993, Evolution of neuropeptide Y and its related peptides, Comp. Biochem. Physiol. C, 106, 743 George, 2014, New and emerging drug molecules against obesity, J. Cardiovasc. Pharmacol. Ther., 19, 65, 10.1177/1074248413501017 Ziauddeen, 2013, Central nervous system biomarkers for antiobesity drug development, Drug Discov. Today, 18, 1282, 10.1016/j.drudis.2013.08.015 Stanley, 1993, Feeding responses to perifornical hypothalamic injection of neuropeptide Y in relation to circadian rhythms of eating behavior, Peptides, 14, 475, 10.1016/0196-9781(93)90135-4 Suzuki, 2012, Obesity and appetite control, Exp. Diabetes Res., 824305 Leibowitz, 2004, Hypothalamic control of energy balance: different peptides different functions, Peptides, 25, 473, 10.1016/j.peptides.2004.02.006 Mercer, 2011, The role of NPY in hypothalamic mediated food intake, Front. Neuroendocrinol., 32, 398, 10.1016/j.yfrne.2011.06.001 Zhang, 2014, Hypothalamus-adipose tissue crosstalk: neuropeptide Y and the regulation of energy metabolism, Nutr. Metab., 11, 27, 10.1186/1743-7075-11-27 Kohno, 2012, Arcuate NPY neurons sense and integrate peripheral metabolic signals to control feeding, Neuropeptides, 46, 315, 10.1016/j.npep.2012.09.004 Stanley, 2005, Hormonal regulation of food intake, Physiol. Rev., 85, 1131, 10.1152/physrev.00015.2004 Barson, 2012, Neurobiology of consummatory behavior: mechanisms underlying overeating and drug use, ILAR J., 53, 35, 10.1093/ilar.53.1.35 Broberger, 1998, The neuropeptide Y/agouti gene-related protein (AGRP) brain circuitry in normal anorectic, and monosodium glutamate-treated mice, Proc. Natl. Acad. Sci. U. S. A., 95, 15043, 10.1073/pnas.95.25.15043 Cone, 2005, Anatomy and regulation of the central melanocortin system, Nat. Neurosci., 8, 571, 10.1038/nn1455 Haskell-Luevano, 1999, Characterization of the neuroanatomical distribution of agouti-related protein immunoreactivity in the rhesus monkey and the rat, Endocrinology, 140, 1408, 10.1210/endo.140.3.6544 Nijenhuis, 2001, AgRP (83–132) acts as an inverse agonist on the human-melanocortin-4 receptor, Mol. Endocrinol., 15, 164 Marks, 2004, Ala67Thr polymorphism in the Agouti-related peptide gene is associated with inherited leanness in humans, Am. J. Med. Genet. A, 126A, 267, 10.1002/ajmg.a.20600 Bjørbæk, 2009, Central leptin receptor action and resistance in obesity, J. Investig. Med., 57, 789, 10.2310/JIM.0b013e3181bb0d49 Ollmann, 1997, Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein, Science, 278, 135, 10.1126/science.278.5335.135 Shutter, 1997, Hypothalamic expression of ART a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice, Genes Dev., 11, 593, 10.1101/gad.11.5.593 Hagan, 2000, Long-term orexigenic effects of AgRP-(83–-132) involve mechanisms other than melanocortin receptor blockade, Am. J. Physiol. Regul. Integr. Comp. Physiol., 279, R47, 10.1152/ajpregu.2000.279.1.R47 Schwartz, 2000, Central nervous system control of food intake, Nature, 404, 661, 10.1038/35007534 Gropp, 2005, Agouti-related peptide-expressing neurons are mandatory for feeding, Nat. Neurosci., 8, 1289, 10.1038/nn1548 Weston-Green, 2012, Alterations to melanocortinergic GABAergic and cannabinoid neurotransmission associated with olanzapine, PLoS One, 7, e33548, 10.1371/journal.pone.0033548 Zhang, 2014, Hypothalamic ghrelin signalling mediates olanzapine-induced hyperphagia and weight gain in female rats, Int. J. Neuropsychopharmacol., 17, 807, 10.1017/S1461145713001697 Nikisch, 2012, Quetiapine affects neuropeptide Y and corticotropin-releasing hormone in cerebrospinal fluid from schizophrenia patients: relationship to depression and anxiety symptoms and to treatment response, Int. J. Neuropsychopharmacol., 15, 1051, 10.1017/S1461145711001556 Kirk, 2006, Clozapine but not haloperidol, increases neuropeptide Y neuronal expression in the rat hypothalamus, J. Psychopharmacol. (Oxf.), 20, 577, 10.1177/0269881106061199 Ehrlich, 2012, Trajectories of agouti-related protein and leptin levels during antipsychotic-associated weight gain in patients with schizophrenia, J. Clin. Psychopharmacol., 32, 767, 10.1097/JCP.0b013e318270e5c5 Ruano, 2007, Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients, Mol. Psychiatry, 12, 474, 10.1038/sj.mp.4001944 Tiwari, 2013, Association of a functional polymorphism in neuropeptide Y with antipsychotic-induced weight gain in schizophrenia patients, J. Clin. Psychopharmacol., 33, 11, 10.1097/JCP.0b013e31827d145a Jorgensen, 2005, Histaminergic neurons are involved in the orexigenic effect of orexin-A, Neuroendocrinology, 82, 70, 10.1159/000090982 MortonM.W. Schwartz, 2001, The NPY/AgRP neuron and energy homeostasis, Int. J. Obes. Relat. Metab. Disord., 25, S56, 10.1038/sj.ijo.0801915 Slominski, 2000, Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress, Physiol. Rev., 80, 979, 10.1152/physrev.2000.80.3.979 Millington, 2006, Pro-opiomelanocortin (POMC): the cutaneous roles of its melanocortin products and receptors, Clin. Exp. Dermatol., 31, 407, 10.1111/j.1365-2230.2006.02128.x Patel, 2011, Melanocortin receptors as novel effectors of macrophage responses in inflammation, Front. Immunol., 2, 41, 10.3389/fimmu.2011.00041 Wang, 2015, Whole-brain mapping of the direct inputs and axonal projections of POMC and AgRP neurons, Front. Neuroanat., 9, 40, 10.3389/fnana.2015.00040 Jobst, 2004, The electrophysiology of feeding circuits, Trends Endocrinol. Metab., 15, 488, 10.1016/j.tem.2004.10.007 Baker, 2005, Association between common polymorphisms of the proopiomelanocortin gene and body fat distribution: a family study, Diabetes, 54, 2492, 10.2337/diabetes.54.8.2492 Ternouth, 2011, Association study of POMC variants with body composition measures and nutrient choice, Eur. J. Pharmacol., 660, 220, 10.1016/j.ejphar.2010.10.112 Yaswen, 1999, Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin, Nat. Med., 5, 1066, 10.1038/12506 Hagan, 1999, Role of the CNS melanocortin system in the response to overfeeding, J. Neurosci., 19, 2362, 10.1523/JNEUROSCI.19-06-02362.1999 Millington, 2007, The role of proopiomelanocortin (POMC) neurones in feeding behaviour, Nutr. Metab., 4, 18, 10.1186/1743-7075-4-18 Reynolds, 2010, Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms, ‎Pharmacol. Ther, 125, 169, 10.1016/j.pharmthera.2009.10.010 Kim, 2010, Enhanced hypothalamic leptin signaling in mice lacking dopamine D2 receptors, J. Biol. Chem., 285, 8905, 10.1074/jbc.M109.079590 Tiligada, 1989, Regulation of alpha-melanocyte-stimulating hormone release from superfused slices of rat hypothalamus by serotonin and the interaction of serotonin with the dopaminergic system inhibiting peptide release, Brain Res., 503, 225, 10.1016/0006-8993(89)91668-5 Vicentic, 2007, The CART (cocaine- and amphetamine-regulated transcript) system in appetite and drug addiction, J. Pharmacol. Exp. Ther., 320, 499, 10.1124/jpet.105.091512 Zhang, 2012, Roles of cocaine- and amphetamine-regulated transcript in the central nervous system, Clin. Exp. Pharmacol. Physiol., 39, 586, 10.1111/j.1440-1681.2011.05642.x Douglass, 1996, Characterization of the human cDNA and genomic DNA encoding CART: a cocaine- and amphetamine-regulated transcript, Gene, 169, 241, 10.1016/0378-1119(96)88651-3 Kristensen, 1998, Hypothalamic CART is a new anorectic peptide regulated by leptin, Nature, 393, 72, 10.1038/29993 Nakhate, 2011, Central regulation of feeding behavior during social isolation of rat: evidence for the role of endogenous CART system, Int. J. Obes., 35, 773, 10.1038/ijo.2010.231 Simpson, 2009, Hypothalamic regulation of food intake and clinical therapeutic applications, Arq. Bras. Endocrinol. Metabol., 53, 120, 10.1590/S0004-27302009000200002 Davidowa, 2005, The main effect of cocaine- and amphetamine-regulated transcript (CART) peptide on hypothalamic neuronal activity depends on the nutritional state of rats, Neuro Endocrinol. Lett., 26, 29 Cota, 2006, Leptin in energy balance and reward: two faces of the same coin?[comment], Neuron, 51, 678, 10.1016/j.neuron.2006.09.009 Di Marzo, 2009, The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulation, Int. J. Obes., 33, S18, 10.1038/ijo.2009.67 Rohner-Jeanrenaud, 2002, Chronic central infusion of cocaine- and amphetamine-regulated transcript (CART 55–102): effects on body weight homeostasis in lean and high-fat-fed obese rats, Int. J. Obes. Relat. Metab. Disord., 26, 143, 10.1038/sj.ijo.0801863 Sezlev, 2013, The role of central neuropeptides in weight gain caused by olanzapine, Eur. Psychiatry, 28, 1, 10.1016/S0924-9338(13)77354-1 Donovan, 2013, Serotonin and the regulation of mammalian energy balance, Front. Neurosci., 7, 36, 10.3389/fnins.2013.00036 Chowdhury, 2014, Investigation of melanocortin system gene variants in antipsychotic-induced weight gain, World J. Biol. Psychiatry, 15, 251, 10.3109/15622975.2013.858827 Malhotra, 2012, Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-Induced weight gain, Arch. Gen. Psychiatry, 69, 904, 10.1001/archgenpsychiatry.2012.191 Malmberg-Aiello, 1998, Evidence for hypernociception induction following histamine H1 receptor activation in rodents, Life Sci., 63, 463, 10.1016/S0024-3205(98)00295-1 Jeck-Thole, 2006, Betahistine: a retrospective synopsis of safety data, Drug Saf., 29, 1049, 10.2165/00002018-200629110-00004 Tighilet, 2007, Histaminergic ligands improve vestibular compensation in the cat: behavioural: neurochemical and molecular evidence, Eur. J. Pharmacol., 568, 149, 10.1016/j.ejphar.2007.04.052 Barak, 2008, Betahistine: what's new on the agenda, Expert Opin. Investig. Drugs, 17, 795, 10.1517/13543784.17.5.795 Szelag, 2001, Betahistine inhibits food intake in rats, Pol. J. Pharmacol., 53, 701 Deng, 2012, Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model, J. Psychopharmacol. (Oxf.), 26, 1271, 10.1177/0269881112449396 Lieberman, 2005, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia, N. Engl. J. Med., 353, 1209, 10.1056/NEJMoa051688 Barak, 2008, Effect of histaminergic manipulation on weight in obese adults: a randomized placebo controlled trial, Int. J. Obes., 32, 1559, 10.1038/ijo.2008.135 Ali, 2010, Acute effects of betahistine hydrochloride on food intake and appetite in obese women: a randomized, placebo-controlled trial, Am. J. Clin. Nutr., 92, 1290, 10.3945/ajcn.110.001586 Poyurovsky, 2005, The effect of betahistine a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients, Int. Clin. Psychopharmacol., 20, 101, 10.1097/00004850-200503000-00007 Poyurovsky, 2013, Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine–betahistine combination, Psychopharmacology (Berl.), 226, 615, 10.1007/s00213-012-2935-2 Poyurovsky, 2007, Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study, Psychopharmacology (Berl.), 192, 441, 10.1007/s00213-007-0731-1 N. Barak, Y. Beck, Betahistine safely mitigates olanzapine induced weight gain and sleepiness, Collegium Internationale Neuro-Psychopharmacoloicum XXVII World Congress, Vol. 13, Hongkong, China, 2010, p. 87. L. Maayan, The attenuation of second generation antipsychotic induced weight gain in adolescents and young adults using betahistine: a double-blind, placebo-controlled trial. http://www.clinicalconnection.com/exp/EPVS.aspx?studyID=258108&slID=1439477 (accessed 30.06.15). He, 2014, Olanzapine-activated AMPK signaling in the dorsal vagal complex is attenuated by histamine H1 receptor agonistin female rats, Endocrinology, 155, 4895, 10.1210/en.2014-1326 Meltzer, 2007, Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden, Proc. Natl. Acad. Sci. U.S.A., 104, 3019, 10.1073/pnas.0700090104 Stefanidis, 2008, The role of thermogenesis in antipsychotic drug-induced weight gain, Obesity, 17, 16, 10.1038/oby.2008.468 Lopez, 2008, Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin, Cell Metab., 7, 389, 10.1016/j.cmet.2008.03.006 Itoh, 1999, Thioperamide, a histamine H3 receptor antagonist, powerfully suppresses peptide YY-induced food intake in rats, Biol. Psychiatry, 45, 475, 10.1016/S0006-3223(98)00044-4 Yoshimatsu, 2006, The neuronal histamine H1 and pro-opiomelanocortin-melanocortin 4 receptors: independent regulation of food intake and energy expenditure, Peptides, 27, 326, 10.1016/j.peptides.2005.02.028 Lopez, 2010, Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance, Nat. Med., 16, 1001, 10.1038/nm.2207 Morrison, 2014, Central neural regulation of brown adipose tissue thermogenesis and energy expenditure, Cell Metab., 19, 741, 10.1016/j.cmet.2014.02.007 Wan, 2014, Evidence for the role of AMPK in regulating PGC-1 alpha expression and mitochondrial proteins in mouse epididymal adipose tissue, Obesity (Silver Spring), 22, 730, 10.1002/oby.20605 Zhang, 2014, Olanzapine reduced brown adipose tissue thermogenesis and locomotor activity in female rats, Prog. Neuropsychopharmacol. Biol. Psychiatry., 51, 172, 10.1016/j.pnpbp.2014.02.003 Horacek, 2006, Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia, CNS Drugs, 20, 389, 10.2165/00023210-200620050-00004 Meltzer, 2011, The role of serotonin receptors in the action of atypical antipsychotic drugs, Curr. Opin. Pharmacol., 11, 59, 10.1016/j.coph.2011.02.007 Bozina, 2007, Association study of olanzapine-induced weight gain and therapeutic response with SERT gene polymorphisms in female schizophrenic patients, J. Psychopharmacol. (Oxf.), 21, 728, 10.1177/0269881106072750 Zhang, 2011, Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction, Expert Opin. Drug Metab. Toxicol., 7, 9, 10.1517/17425255.2011.532787 Ginovart, 2012, Role of dopamine D2 receptors for antipsychotic activity, Handb. Exp. Pharmacol., 212, 27, 10.1007/978-3-642-25761-2_2 Seeman, 2011, All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors, CNS Neurosc. Ther., 17, 118, 10.1111/j.1755-5949.2010.00162.x Howes, 2012, The nature of dopamine dysfunction in schizophrenia and what this means for treatment, Arch. Gen. Psychiatry, 69, 776, 10.1001/archgenpsychiatry.2012.169 Lian, 2013, Effects of olanzapine and betahistine co-treatment on serotonin transporter: 5-HT2A and dopamine D2 receptor binding density, Prog. Neuropsychopharmacol. Biol. Psychiatry., 47, 62, 10.1016/j.pnpbp.2013.08.005 Lian, 2015, Chronic betahistine co-treatment reverses olanzapine's effects on dopamine D(2) but not 5-HT2A/2C bindings in rat brains, Prog. Neuropsychopharmacol. Biol. Psychiatry, 56, 75, 10.1016/j.pnpbp.2014.08.006 Kuroki, 2008, Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis, vol. 172, 199 Tarazi, 2002, Long-term effects of olanzapine risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions, Psychopharmacology (Berl.), 161, 263, 10.1007/s00213-002-1016-3 Reynolds, 2005, The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment, Prog. Neuropsychopharmacol. Biol. Psychiatry, 29, 1021, 10.1016/j.pnpbp.2005.03.019 Tarazi, 2001, Long-term effects of olanzapine risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment, J. Pharmacol. Exp. Ther., 297, 711 Samaha, 2007, Breakthrough dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time, J. Neurosci., 27, 2979, 10.1523/JNEUROSCI.5416-06.2007 Lacour, 2001, Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action, CNS Drugs, 15, 853, 10.2165/00023210-200115110-00004 Fossati, 2001, Binding affinity profile of betahistine and its metabolites for central histamine receptors of rodents, Pharmacol. Res., 43, 389, 10.1006/phrs.2000.0795